Marker Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Marker Therapeutics

04/11/2022 17:11

* Marker Therapeutics Inc  MRKR.OQ   MRKR.O  is expected
to show a
rise in quarterly revenue when it reports  results on November 8
(estimated). 
    * The Houston Texas-based  company is expected to report
revenue
of $266.67 thousand, according to the mean estimate from 3
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Marker Therapeutics
Inc
is for a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Marker
Therapeutics Inc is $1.5​, above​ its last closing price
of $0.41. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.11       -0.13      -0.11     Beat    13.2
 Mar. 31 2022  -0.14       -0.13      -0.12     Beat    10
 Dec. 31 2021              -0.13      -0.12     Beat    5.9​
 Sep. 30 2021  -0.13       -0.13      -0.12     Beat    5.9
 ​​Jun.        -0.13       -0.12      -0.13     Missed  -10.6
 30 2021                                                
 Mar. 31 2021  -0.12       -0.14      -0.16     Missed  -10.3​
 Dec. 31 2020  -0.16       -0.16      -0.18     Missed  -12.5
 Sep. 30 2020              -0.14      -0.16     Missed  -11.6
 This summary was machine generated November 4 at 17:11 GMT.  All
figures in US dollars  unless otherwise stated